Last reviewed · How we verify
BECLABUVIR
Beclabuvir, marketed by Bristol-Myers Squibb, is a chronic hepatitis C treatment that blocks the potassium voltage-gated channel subfamily H member 2 to inhibit viral replication. Its key strength lies in its unique mechanism of action, distinguishing it from other direct-acting antivirals in the same class. The primary risk is the competitive landscape, with multiple same-class drugs already on the market, including ribavirin, telaprevir, boceprevir, simeprevir, and daclatasvir, all of which have varying patent protections and FDA approvals.
At a glance
| Generic name | BECLABUVIR |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Target | Potassium voltage-gated channel subfamily H member 2 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Chronic hepatitis C
Common side effects
Key clinical trials
- Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
- Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV (PHASE2)
- Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BECLABUVIR CI brief — competitive landscape report
- BECLABUVIR updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI